We are here for the people we serve in their pursuit of healthy lives. This has been the way of Abbott for more than a century—passionately and thoughtfully translating science into lasting contributions to health.
Our products encircle life, from newborns to aging adults, from nutrition and diagnostics through medical care and pharmaceutical therapy.
Caring is central to the work we do and defines our responsibility to those we serve.
We advance leading-edge science and technologies that hold the potential for significant improvements to health and to the practice of healthcare.
We value our diversity—that of our products, technologies, markets and people—and believe that diverse perspectives combined with shared goals inspire new ideas and better ways of addressing changing health needs.
We focus on exceptional performance—a hallmark of Abbott people worldwide—demanding of ourselves and each other because our work impacts people’s lives.
We strive to earn the trust of those we serve by committing to the highest standards of quality, excellence in personal relationships, and behavior characterized by honesty, fairness and integrity.
We sustain success—for our business and the people we serve—by staying true to key tenets upon which our company was founded over a century ago: innovative care and a desire to make a meaningful difference in all that we do.
The promise of our company is in the promise that our work holds for health and life.

Research Grants 109 show all


$880.7K
2006

Publications 3,805 show all

  • 114
    Enzyme Inhibitors/pharmacology
  • 67
    Drug Design
  • 61
    Anti-Bacterial Agents/pharmacology
  • 59
    Chromatography, High Pressure Liquid/methods
  • 58
    Enzyme Inhibitors/chemical synthesis
  • 51
    Pyridines/pharmacology
  • 50
    Erythromycin/analogs & derivatives
  • 48
    Renin/antagonists & inhibitors
  • 46
    Hydroxyurea/analogs & derivatives
  • 42
    Histamine Antagonists/pharmacology

Patents 40,650show all

19,391Issued16,704Applications

Clinical Trials 1,001show all

219Phase 3159Phase 2151Phase 4105Phase 199N/A42Other

SEC Filings show all


208
8-K

75
10-Q

22
10-K

4
D

Contact Information

Lake Bluff, IL
United States

SEC Form D Funding Events

DateOfferedSoldType
2011-03-15$100,000$100,000Debt
2010-03-12$70,000$70,000Debt
2009-03-13$6,690,000$6,690,000Debt
2008-03-17UnknownUnknownOther (Paper Filing)

Key Executives

  • Miles D. White
    Executive Officer
  • Richard W. Ashley
    Executive Officer
  • John M. Capek
    Executive Officer
  • Thomas C. Freyman
    Executive Officer
  • Holger A. Liepmann
    Executive Officer
  • Edward L. Michael
    Executive Officer
  • Laura J. Schumacher
    Executive Officer
  • James L. Tyree
    Executive Officer
  • Olivier Bohuon
    Executive Officer
  • Thomas F. Chen
    Executive Officer
  • Stephen R. Fussell
    Executive Officer
  • Robert B. Hance
    Executive Officer
  • John C. Landgraf
    Executive Officer
  • Greg W. Linder
    Executive Officer
  • Heather L. Mason
    Executive Officer
  • James V. Mazzo
    Executive Officer
  • Donald V. Patton Jr.
    Executive Officer
  • Mary T. Szela
    Executive Officer
  • Michael J. Warmuth
    Executive Officer
  • Robert J. Alpern
    Director
  • Roxanne S. Austin
    Director
  • William M. Daley
    Director
  • W. James Farrell
    Director
  • H. Laurance Fuller
    Director
  • William A. Osborn
    Director
  • David A. L. Owen
    Director
  • Boone Powell Jr.
    Director
  • W. Ann Reynolds
    Director
  • Roy S. Roberts
    Director
  • Samuel C. Scott III
    Director
  • William D. Smithburg
    Director
  • Glenn F. Tilton
    Director
  • Carlos Alban
    Executive Officer
  • J. Scott White
    Executive Officer
  • David A.l. Owen
    Director
  • Richard A. Gonzalez
    Executive Officer
  • Brian J. Blaser
    Executive Officer
  • A. David Forrest
    Executive Officer
  • Edward M. Liddy
    Director
  • Phebe N. Novakovic
    Director